You Might Also Like
Explore This IssueDecember 2018
Also By This Author
In 2011, the FDA approved rituximab combined with glucocorticoids to treat adult patients with GPA and MPA, with the precaution that limited data were available on the safety and efficacy of subsequent courses in these patients. The safety and efficacy of rituximab retreatment had not yet been established.2
The MAINRITSAN trial evaluated the efficacy and safety of rituximab compared with azathioprine as follow-up treatment for ANCA-associated vasculitis, such as GPA and MPA. To participate, study patients (N=115; 86 with GPA, 24 with MPA, five with renal-limited ANCA-associated vasculitis) had to have achieved disease control after remission induction with cyclophosphamide and glucocorticoids. The follow-up regimen consisted of rituximab with glucocorticoids.
The study’s primary endpoint was the occurrence of major relapse by Month 28. The study defined major relapse as the reappearance of clinical and/or laboratory signs of vasculitis activity that could be life threatening or lead to organ failure or damage.
At Month 28, three patients (5%) on the rituximab regimen achieved the primary endpoint. By Month 28, 17 patients (29%) in the azathioprine-treated group achieved the primary endpoint.
As a result of this research, the label update will remove the precaution for GPA and MPA from rituximab’s prescribing information.
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
- Genentech Inc. News release: FDA approves label update for Genentech’s Rituxan (rituximab) in two rare forms of vasculitis. 2018 Oct 19.
- U.S. Department of Health and Human Services. Letter: Supplemental BLA approval for rituximab. 2011 Apr 19.